Comparación de las características fenotípicas entre los respondedores y los no respondedores al tratamiento de la apnea obstructiva del sueño mediante dispositivos de avance mandibular.

  1. Sara Camañes Gonzalvo 1
  2. Rocío Marco Pitarch 1
  3. Carlos Bellot Arcís 1
  4. Marina García Selva 1
  5. Andrés Plaza Espín 1
  6. Vanessa Paredes Gallardo 1
  1. 1 Universitat de València
    info

    Universitat de València

    Valencia, España

    ROR https://ror.org/043nxc105

Journal:
Ortodoncia española: Boletín de la Sociedad Española de Ortodoncia

ISSN: 0210-1637

Year of publication: 2024

Volume: 62

Issue: 2

Pages: 25-41

Type: Article

More publications in: Ortodoncia española: Boletín de la Sociedad Española de Ortodoncia

Abstract

OBJECTIVE: Mandibular advancement devices (MAD) are considered an effective option for treating obstructive sleep apnea (OSA). However, therapeutic response can vary. The current research aims to identify phenotypic characteristics that differentiate responders from nonresponders to MAD treatment, with the goal of developing a response prediction model. MATERIALS AND METHODS: Baseline clinical, polysomnographic, and anatomical phenotypic features were analyzed, from patients diagnosed with OSA by polysomnography who were treated with MAD, in order to differentiate responders from non-responders. Finally, a response prediction model for MAD treatment was developed using multivariate logistic regression. RESULTS: Phenotypic characteristics of 65 patients were analyzed. Of these, 33 patients responded and 32 did not respond to oral device treatment. Multivariate logistic regression showed that increased anterior facial height (OR=0.613), higher baseline body mass index (BMI) (OR=0.551), longer upper airway length (OR=0.815), and lower baseline minimum oxygen saturation (OR=1.132) may decrease treatment response rates. CONCLUSIONS: Anterior facial height, baseline BMI, upper airway length, and baseline minimum oxygen saturation together constitute a model for predicting response to MAD treatment in OSA patients.